Formulation and Optimization of Oral Mucoadhesive Patches of Myrtus Communis by Box Behnken Design

Hashemi, Mahbubeh; Ramezani, Vahid; Seyedabadi, Mohammad; Ranjbar, A.M.; Jafari-Nodoushan, Hossein; Honarvar, Mina; Fanaei, Hamed

doi:10.15171/apb.2017.053

Cited by 20 publications

(18 citation statements)

References 49 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No entanto, faltam estudos que avaliem o uso de extratos vegetais para fins odontológicos, principalmente na área da medicina veterinária (Pereira et al, 2011). A partir de inúmeras espécies de plantas medicinais é possível obter compostos bioativos para uso em medicamentos e produtos de higiene e beleza (Ferreira et al, 2014;Hashemi et al, 2017). Diversos estudos relatam que as diferentes atividades farmacológicas apresentadas pelos extratos vegetais estão associadas aos compostos orgânicos provenientes do metabolismo primário ou secundário das plantas, tais como flavonoides, taninos, alcaloides, saponinas e terpenos (Kuete et al, 2006).…”

Section: Introductionunclassified

Prospección de extractos de plantas como complementos de la higiene bucal en perros Labrador Retriever

Bolzan¹,

Severi²,

Villanova³

et al. 2020

Pubvet

View full text Add to dashboard Cite

O objetivo do presente estudo foi prospectar extratos vegetais como recurso terapêutico, frente à microbiota oral de cães. Para tal, foram obtidos extratos etanólicos de diferentes partes do Anacardium ocidentalis (cajueiro), Stryphnodendron adstringens (barbatimão), Punica granatum (romã), Uncaria tomentosa (unha de gato), Psidium guajava L.(goiaba), Momordica charantia L. (melão de São Caetano) e Harpagophytum procumbens (garra do diabo), preparados em diferentes concentrações. Microrganismos coletados da mucosa oral de 12 cães da raça Labrador, mantidos sob o mesmo manejo e alimentação, foram semeados em placas de petri com Agar BHI nas quais foram distribuídos circularmente discos de papel impregnados com 20µL de cada extrato em diferentes concentrações. Solução de digluconato de clorexidina a 0,12% em discos foi utilizada como controle positivo. Foram coletados três swabs de cada animal sendo então o experimento realizado em triplicata. As placas foram incubadas por 12 horas, a 36º C. Os resultados das medidas dos halos de inibição foram submetidos à análise de variância de Kruskall-Wallis, seguida do teste de Dunn, com nível de significância de 5%. Com base nos resultados os extratos de romã, goiaba e barbatimão foram selecionados, pois mostraram-se estatisticamente significativos nas concentrações 250; 125; 62,6mg/mL o que sugere que os três extratos são candidatos potenciais para uso no desenvolvimento de produtos farmacêuticos para uso na higienização bucal dos cães.

show abstract

Section: Introductionunclassified

Prospección de extractos de plantas como complementos de la higiene bucal en perros Labrador Retriever

Bolzan¹,

Severi²,

Villanova³

et al. 2020

Pubvet

View full text Add to dashboard Cite

show abstract

“…For the evaluation of tensile strength, the buccal patches (200 mm 2 ) were held between two fixed and movable clamps. The patches were pulled by the movable clamp at a rate of 2 mm/s and then the force was measured when the patches broke 39,40

Tensile strength = \frac{Force at break}{Cross - sectional area of the patch} \times 100

…”

Section: Methodsmentioning

confidence: 99%

“…A preload of 20 g was placed over the probe for 2 min as a pressure for an initial attachment of the patch with the mucosal membrane. The maximum required weight to detach the patch from the mucosal surface indicates the mucoadhesive strength 39 . In addition, force of adhesion and bond strength were calculated from mucoadhesive strength through Equations (4) and (5), respectively.

Force of adhesion ((), N) = \frac{Mucoadhesive strength}{1000} \times 9.81

Bond strength ((), normalN / m^{2}) = \frac{Force of adhesion}{Surface area of patch}

…”

Section: Methodsmentioning

confidence: 99%

Fabrication of multifunctional mucoadhesive buccal patch for drug delivery applications

Shirvan

Hemmatinejad

Bahrami

et al. 2021

J Biomedical Materials Res

View full text Add to dashboard Cite

Mucoadhesive buccal patch is a promising dosage form for a successful oral drug delivery, which provides unique advantages for various applications such as treatment of periodontal disease and postdental surgery disorders. The aim of this study is to synthesize a novel multifunctional mucoadhesive buccal patch in a multilayer reservoir design for therapeutic applications. The patches were fabricated through simultaneous electrospinning of chitosan/poly(vinylalcohol) (PVA)/ibuprofen and electrospraying of phenylalanine amino acid nanotubes (PhNTs) containing metronidazole into the electrospun mats through a layer‐by‐layer process. An electrospun poly(caprolactone) (PCL) was used as an impermeable backing layer to protect the mucoadhesive component from tongue movement and drug loss. Buccal patches were characterized using scanning electron microscopy (SEM) and field emission scanning electron microscopy (FESEM) and also evaluated in terms of physicomechanical parameters such as pH, weight, thickness, tensile strength, folding endurance, and mucoadhesive properties. The swelling index of the patches was examined with respect to the PVA/chitosan ratio. The effect of genipin addition to the electrospinning solution was also studied on mucoadhesive and swelling properties. The cell viability of buccal patches was assessed by methylthiazolydiphenyl‐tetrazolium bromide test on L929 fibroblast cell line. The patch with an optimal amount of mucoadhesive polymers (PVA/chitosan 80:20) and crosslinking agent (0.05 g) indicated an ideal hemostatic activity along with antibacterial properties against Streptococcus mutans bacteria. The synthesized multifunctional mucoadhesive patch with a novel composition and design has a great potential for oral therapeutic applications.

show abstract

“…The results are an encouraging step towards the development of another non-invasive anti-diabetic therapeutic option in the form of sustained-release mucoadhesive patches promoting oral peptide delivery to improve patient compliance and drug adherence. 239 , 240 …”

Section: Insulinmentioning

confidence: 99%

Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice

Shah

Abdalla

Deshmukh

et al. 2021

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a chronic, progressive, and multifaceted illness resulting in significant physical and psychological detriment to patients. As of 2019, 463 million people are estimated to be living with DM worldwide, out of which 90% have type-2 diabetes mellitus (T2DM). Over the years, significant progress has been made in identifying the risk factors for developing T2DM, understanding its pathophysiology and uncovering various metabolic pathways implicated in the disease process. This has culminated in the implementation of robust prevention programmes and the development of effective pharmacological agents, which have had a favourable impact on the management of T2DM in recent times. Despite these advances, the incidence and prevalence of T2DM continue to rise. Continuing research in improving efficacy, potency, delivery and reducing the adverse effect profile of currently available formulations is required to keep pace with this growing health challenge. Moreover, new metabolic pathways need to be targeted to produce novel pharmacotherapy to restore glucose homeostasis and address metabolic sequelae in patients with T2DM. We searched PubMed, MEDLINE, and Google Scholar databases for recently included agents and novel medication under development for treatment of T2DM. We discuss the pathophysiology of T2DM and review how the emerging anti-diabetic agents target the metabolic pathways involved. We also look at some of the limiting factors to developing new medication and the introduction of unique methods, including facilitating drug delivery to bypass some of these obstacles. However, despite the advances in the therapeutic options for the treatment of T2DM in recent years, the industry still lacks a curative agent.

show abstract

Formulation and Optimization of Oral Mucoadhesive Patches of Myrtus Communis by Box Behnken Design

Cited by 20 publications

References 49 publications

Prospección de extractos de plantas como complementos de la higiene bucal en perros Labrador Retriever

Prospección de extractos de plantas como complementos de la higiene bucal en perros Labrador Retriever

Fabrication of multifunctional mucoadhesive buccal patch for drug delivery applications

Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice

Contact Info

Product

Resources

About